Joshua N. Baugh, Sophie Veldhuijzen van Zanten, Marta Fiocco, Niclas Colditz, Marion Hoffmann, Geert O. Janssens, Chiara Valentini, Darren Hargrave, Maria Wiese, André O. von Bueren, Michael Karremann, Thomas Perwein, Gunther Nussbaumer, Martin Benesch, Dominik Sturm, Gerrit H. Gielen, Mechthild Krause, Matthias Eyrich, Eelco W. Hoving, Brigitte Bison, Dannis G. van Vuurden, Christof M. Kramm
- Background
Our aim is to investigate the association of treatment with survival in patients with diffuse intrinsic pontine glioma (DIPG) by examining 6 historical treatment paths.
Methods
We retrospectively analyzed data from 409 patients with radiologically centrally reviewed DIPG, sourced from the German Society of Pediatric Oncology and Hematology HIT-HGG trial database and the SIOPE-DIPG/DMG Registry. Survival outcomes were estimated using the Kaplan–Meier method, and univariable and multivariable Cox proportional hazard models were estimated to study treatment effects.
Results
The median overall survival (OS) from diagnosis was 11.2 months (95% confidence interval [CI], 10.5–11.9). Patients who by choice received no frontline treatment had an OS of 3.0 months (95% CI, 2.0–4.0), while those treated with radiation therapy (RT) alone had a median OS of 10.4 months (95% CI, 9.1–11.8). Those receiving RT combined with chemotherapy had the longest median OS of 11.7 monthsBackground
Our aim is to investigate the association of treatment with survival in patients with diffuse intrinsic pontine glioma (DIPG) by examining 6 historical treatment paths.
Methods
We retrospectively analyzed data from 409 patients with radiologically centrally reviewed DIPG, sourced from the German Society of Pediatric Oncology and Hematology HIT-HGG trial database and the SIOPE-DIPG/DMG Registry. Survival outcomes were estimated using the Kaplan–Meier method, and univariable and multivariable Cox proportional hazard models were estimated to study treatment effects.
Results
The median overall survival (OS) from diagnosis was 11.2 months (95% confidence interval [CI], 10.5–11.9). Patients who by choice received no frontline treatment had an OS of 3.0 months (95% CI, 2.0–4.0), while those treated with radiation therapy (RT) alone had a median OS of 10.4 months (95% CI, 9.1–11.8). Those receiving RT combined with chemotherapy had the longest median OS of 11.7 months (95% CI, 10.8–12.6). The median post-progression survival (PPS) was 4.1 months (95% CI, 3.5–4.7). Patients who relapsed and did not receive treatment had a PPS of 2.2 months (95% CI, 1.8–2.6), while those treated with chemotherapy alone had a PPS of 4.4 months (95% CI, 3.7–5.0), and those who underwent reirradiation, with or without chemotherapy, had the longest survival after relapse of 6.6 months (95% CI, 5.3–8.0). Treatment differences remained significant in multivariable analysis adjusted for age and symptom duration in both diagnosis and relapse setting.
Conclusions
This study shows increased survival outcomes associated with radiation and chemotherapy treatment or a combination thereof, at diagnosis and relapse, in a historical DIPG cohort.…
